Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11968994 | 0.85 | TAAR1 (0.44) | TAAR1RIPK1ADRA2AADRA2CLMNA | |
| SCHEMBL3367523 | 0.81 | ADRA2A (0.45) | TAAR1RIPK1ADRA2AADRA2CLMNA | |
| SCHEMBL9768717 | 0.81 | TAAR1 (0.41) | TAAR1RIPK1ADRA2AADRA2CLMNA | |
| SCHEMBL14944876 | 0.79 | CYP1A2 (0.42) | TAAR1RIPK1ADRA2AADRA2CLMNA | |
| SCHEMBL14431333 | 0.79 | TAAR1 (0.50) | TAAR1RIPK1ADRA2AADRA2CLMNA | |
| SCHEMBL18470550 | 0.79 | TAAR1 (0.50) | TAAR1RIPK1ADRA2AADRA2CLMNA | |
| SCHEMBL416895 | 0.79 | TAAR1 (0.50) | TAAR1RIPK1ADRA2AADRA2CLMNA | |
| SCHEMBL20706326 | 0.78 | CHRNA7 (0.39) | LMNAALDH1A1SLC6A3 | |
| SCHEMBL29998966 | 0.78 | TAAR1 (0.48) | TAAR1RIPK1ADRA2AADRA2CLMNA | |
| SCHEMBL20306752 | 0.77 | RIPK1 (0.45) | TAAR1RIPK1ADRA2AADRA2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1712 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025136206-A1 | A NASAL DEVICE FOR USE IN DRUG DELIVERY VIA THE NASAL CAVITY | NOSEOPTION AB (SE) | 2025-06-26 | — | — | WO | claimed |
| US-20200060997-A1 | TARR Receptor Agonists for Sexual Dysfunction | JOHN MCCOY | 2020-02-27 | — | — | US | claimed |
| US-10463676-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | ARENA PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | claimed |
| US-20190292164-A1 | PROCESS FOR THE PREPARATION OF GLYCEROL CARBONATE | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2019-09-26 | — | — | US | claimed |
| US-20190275055-A1 | Modified-Release Dosage Forms of 5-Ht2c Agonists Useful for Weight Management | ARENA PHARMACEUTICALS, INC. | 2019-09-12 | — | — | US | claimed |
| EP-3485878-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | Arena Pharmaceuticals, Inc. (US) | 2019-05-22 | — | — | EP | claimed |
| EP-2611427-B1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARM INC (US) | 2018-10-17 | — | — | EP | claimed |
| EP-3366306-A2 | USE OF SOME PEPTIDES IN DIAGNOSIS AND TREATMENT OF DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-08-29 | — | — | EP | claimed |
| EP-3351262-A1 | CURAGLUTIDE FOR IN TREATMENT OF PREDIABETES, DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-07-25 | — | — | EP | claimed |
| CN-107669687-A | 5 HT for body weight control2CThe modified release dosage form of activator | 艾尼纳制药公司 | 2018-02-09 | — | — | CN | claimed |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2003-06-19 | — | — | US | claimed |
| WO-2003045313-A2 | 2-AMINOQUINOLINE COMPOUNDS | MERCK & CO. INC. (US) | 2003-06-05 | — | — | WO | claimed |
| WO-2003045920-A1 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO., INC. (US) | 2003-06-05 | — | — | WO | claimed |
| WO-2003007887-A2 | SUBSTITUTED IMIDAZOLES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-01-30 | — | — | WO | claimed |
| JP-2001524960-A | — | — | 2001-12-04 | — | — | JP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0977572-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 2000-02-09 | — | — | EP | claimed |
| WO-1998047513-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-10-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463676-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | HTR2C, HTR2A, HTR3C | TAAR1 180/4885RIPK1 3328/4885ADRA2A 34/4885 |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | TAAR1 74/4885RIPK1 448/4885ADRA2A 426/4885 |
| US-20190275055-A1 | Modified-Release Dosage Forms of 5-Ht2c Agonists Useful for Weight Management | HTR2C, HTR2A, HTR3C | TAAR1 180/4885RIPK1 3328/4885ADRA2A 34/4885 |
| US-20190292164-A1 | PROCESS FOR THE PREPARATION OF GLYCEROL CARBONATE | GK, DGKI, DGKA | TAAR1 1356/4885RIPK1 1880/4885ADRA2A 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.